Serrata (serratopeptidase) coated enteric tablets 10 mg. №150

Description

Serrata (serratopeptidase) coated enteric tablets 10 mg. №150

Composition

active substance: serratiopeptidase;

1 tablet contains serratiopeptidases 10 mg;

excipients: lactose monohydrate, corn starch, light magnesium carbonate, sodium starch glycolate (type A), magnesium stearate, coating Oradry-YS-1-7027*, coating Opadry-OY-Р-7171**.

* – Coating Opadry-YS-1-7027: hypromellose, titanium dioxide (E 171), triacetin.

** – Opadry-ОY-Р-7171 coating: polyvinyl acetate phthalate, titanium dioxide (E 171), diethyl phthalate, stearic acid.

Medicinal form

Film-coated tablets are enteric-soluble.

Main physico-chemical properties: round biconvex tablets covered with a white enteric coating.

Pharmacotherapeutic group

Means used in pathology of the musculoskeletal system. Enzymes.
ATX code M09A B.

Pharmacological properties

Serratiopeptidase is a proteolytic enzyme isolated from the non-pathogenic intestinal bacterium Serratia E15. It has fibrinolytic, anti-inflammatory and anti-edematous activity. In addition to reducing the inflammatory process, serratiopeptidase relieves pain by blocking the release of painful amines from inflamed tissues.

Serratiopeptidase binds in a 1:1 ratio to blood α-2-macroglobulin, which masks its antigenicity, but preserves its enzymatic activity. Then, gradually at the site of inflammation, it turns into exudate and, accordingly, its level in the blood decreases.

Serratiopeptidase directly reduces the dilatation (expansion) of capillaries and controls their permeability through the hydrolysis of bradykinin, histamine and serotonin. Serratiopeptidase also blocks plasmin inhibitors, thereby promoting the fibrinolytic activity of plasmin. Thanks to the proteolysis of structural proteins of sputum, it improves the rheological properties of sputum and promotes its removal.

The enzymatic activity of the drug is 10 times higher than that of α-chymotrypsin. In the focus of chronic inflammation, serratiopeptidase helps to reduce the level of mediators of inflammation of a polypeptide nature (bradykinin), fibrin, but does not have a significant effect on the proteins of a living organism, such as albumin and α- and γ-globulin.

The drug penetrates well into places of inflammation, lyses necrotized tissues and their decay products, reduces hyperemia and accelerates the penetration and activity of antibiotics. The drug reduces the viscosity of saliva and secretions from the nose, thereby facilitating their removal.

Indications

Serrata tablets has a variety of pharmacological effects, which allows it to be used in a wide variety of areas of medicine. In surgery, the drug is used in the treatment of fractures, dislocations, sprains and edema of various etiologies. In addition, Serrata is used to prevent transplant rejection.
Serrata tablets is also used in plastic surgery to improve blood microcirculation, to prevent transplant rejection and reduce edema after surgery.
In ENT practice, the drug is used to treat otitis media, sinusitis and other inflammatory diseases, accompanied by increased secretion production and difficulty in sputum discharge.
In dermatology, the drug is used for the treatment of acute dermatoses, and in gynecology and obstetrics to reduce edema of the mammary glands of various origins. In addition, the drug is very often used to quickly eliminate hematomas.
In addition, Serrata is prescribed to reduce the viscosity of sputum in respiratory diseases.

Contraindications

Serrata tablets is not prescribed for patients with hypersensitivity to serratiopeptidase, bleeding disorders, and a tendency to bleed. The drug is prescribed with caution to those who suffer from impaired kidney or liver function, pregnant women and women at the lactation stage. In pediatric practice, the drug is used for the treatment of children only for vital signs and under medical supervision.

Application during pregnancy and lactation

Serrata does not have teratogenic or mutagenic effects on the fetus, but the experience of prescribing the drug to pregnant women is very limited, therefore it is carried out only for vital signs and under medical supervision.
When prescribing Serrata to women at the lactation stage, breastfeeding should be abandoned.

Method of administration and dosage

Serrata is available as an oral tablet. The drug is taken regardless of food intake, the tablets are swallowed whole. The duration of therapy and the dose of the drug depends on the dynamics and nature of the disease. The standard dose is 1 tablet 3 r / d, if necessary, the amount of the drug can be increased by the doctor’s decision.

Overdose

When taking increased doses of Serrata, the patient has an increase in side effects. When taking large doses of the drug, internal bleeding may develop. If an overdose symptoms are detected in a patient, the appointment of symptomatic treatment is indicated.

Side effects

When treating Serrata, the patient may develop side effects such as stool disturbance, dyspeptic disorders, abdominal pain, loss of appetite, nosebleeds, sputum production with blood and the development of various allergic reactions.